Recombinant adenovirus expressing wild-type p53 is antiangiogenic: A proposed mechanism for bystander effect

Clinical Cancer Research

Volumn 5, Issue 5, 1999, Pages 1015-1023

  Nishizaki, Masahiko ^a   Fujiwara, Toshiyoshi ^a   Tanida, Tohru ^a   Hizuta, Akio ^a   Nishimori, Hiroyuki ^b   Tokino, Takashi ^b   Nakamura, Yusuke ^b   Bouvet, Michael ^c   Roth, Jack A ^c   Tanaka, Noriaki ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; PROTEIN P53;

ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

ADENOVIRUSES, HUMAN; ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CYTOMEGALOVIRUS; ENDOTHELIAL GROWTH FACTORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENES, P53; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; LYMPHOKINES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BIOSYNTHESIS; PROTEINS; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032902502     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Folkman, J. Tumor angiogenesis. Adv. Cancer Res., 43: 175-203, 1985.
2. Ausprunk, D. H., and Folkman, J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc. Res., 14: 53-65, 1977.
3. Fidler, I. J., and Ellis, L. M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell, 79: 85-88, 1994.
4. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
5. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenesis switch during tumorigenesis. Cell, 86: 353-364, 1996.
6. Hollstein, M., Sideransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
7. Fujiwara, T., Cai, D. W., Georges, R. N., Mukhopadhyay, T., Grimm, E. A., and Roth, J. A. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J. Natl. Cancer Inst. (Bethesda), 86: 1458-1462, 1994.
8. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W-W., Owen-Schaub, L. B., and Roth, J. A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54: 2287-2291, 1994.
9. 1 arrest and induces apoptosis in human cancer cells. Oncogene, 15: 1903-1910, 1997.
10. Ogawa, N., Fujiwara, T., Kagawa, S., Nishizaki, M., Morimoto, Y., Tanida, T., Hizuta, A., Yasuda, T., Roth, J. A., and Tanaka, N. Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent. Int. J. Cancer, 73: 367-370, 1997.
11. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V., and Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (Washington DC), 246: 1306-1309, 1989.
12. Mukhopadhyay, D., Tsiokas, L., Zhou, X., Foster, D., Brugge, J. S., and Sukhatme, V. P. Hypoxie induction of human vascular endothelial growth factor expression through c-Src activation. Nature (Lond.), 375: 577-581, 1995.
13. Shweki, D., Itin, A., Soffer, D., and Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (Lond.), 359: 843-845, 1992.
14. Koura, A. N., Liu, W., Kitadai, Y., Singh, R. K., Radinsky, R., and Ellis, L. M. Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by cell density. Cancer Res., 56: 3891-3894, 1996.
15. Mukhopadhyay, D., Tsiokas, L., and Sukhatme, V. P. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res., 55: 6161-6165, 1995.
16. Nishimori, H., Shiratsuchi, T., Urano, T., Kimura, Y., Kiyono, K., Tatsumi, K., Yoshida, S., Ono, M., Kuwano, M., Nakamura, Y., and Tokino, T. A novel brain-specific p53-target gene, BAII, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene, 15: 2145-2150, 1997.
17. Zhang, W-W., Fang, X., Mazur, W., French, B. A., Georges, R. N., and Roth, J. A. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther., 1: 1-10, 1994.
18. Anthony, F. W., Wheeler, T., Elcock, C. L., Pickett, M., and Thomas, E. J. Identification of a specific pattern of vascular endothelial growth factor mRNA expression in human placenta and cultured placental fibroblasts. Placenta, 15: 557-561, 1994.
19. Morrison, R. S. Suppression of basic fibroblast growth factor expression by antisense oligonucleotides inhibits the growth of transformed human astrocytes. J. Biol. Chem., 266: 728-734, 1991.
20. Bertin, N., Clezardin, P., Kubiak, R., and Frappart, L. Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia. Cancer Res., 57: 396-399, 1997.
21. Tanaka, N., Sakamoto, N., Inoue, K., Korenaga, H., Kadoya, S., Ogawa, H., and Osada, Y. Antitumor effect of an antiangiogenic polysaccharide from an Arthrobacter species with or without steroid. Cancer Res., 49: 6727-6730, 1989.
22. Roth, J. A., Nguyen, D., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Ferson, D. Z., Hong, W. K., Komaki, R., Lee, J. J., Nesbitt, J. C., Pisters, K. M. W., Putnum, J. B., Schea, R., Shin, D. M., Walsh, G. L., Dolormente, M. M., Han, C-I., Martin, F. D., Yen, N., Xu, K., Stephens, L. C., McDonnell, T. J., Mukhopadhyay, T., and Cai, D. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med., 2: 985-991, 1996.
23. Kozaesky, K. F., and Wilson, J. M. Gene therapy: adenovirus vectors. Curr. Opin. Genet. Dev., 3: 499-503, 1993.
24. Xu, M., Kumar, D., Srinvas, S., Detolla, L. J., Yu, S. F., Stass, S. A., and Mixson, A. J. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. Hum. Gene Ther., 8: 177-185, 1997.
25. Keiser, A., Weich, H. A., Brandner, G., Marme, D., and Kolch, W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene, 9: 963-969, 1994.
26. Maeda, K., Chung, Y-S., Ogawa, Y., Takatsuka, S., Kang, S-M., Ogawa, M., Sawada, T., and Sowa, M. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer (Phila.), 77: 858-863, 1996.
27. Ohta, Y., Endo, Y., Tanaka, M., Shimizu, J., Oda, M., Hayashi, Y., Watanabe, Y., and Sasaki, T. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin. Cancer Res., 2: 1411-1416, 1996.
28. Wang, Y., and Becker, D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat. Med., 3: 887-893, 1997.
29. Volpert, O. V., Dameron, K. M., and Bouck, N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity, Oncogene, 14: 1495-1502, 1997.
30. Dameron, K. M., Volpert, O. V., Tainsky, M. A., and Bouck, N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (Washington DC), 265: 1582-1584, 1994.
31. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79: 315-328, 1994.
32. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.